Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus paclitaxel and cisplatin as induction therapy in head and neck squamous cell carcinoma
ChiCTR2400086660Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Objective response rate (ORR), Pathological complete response rate (pCR) and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400086660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086660.